Arthritis, Psoriatic, PsoriasisNCT00303186
Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy
An observational study of Arthritis, Psoriatic, Psoriasis, run by Pfizer at 9 sites in Italy.
Trial summary
The purpose of this study is to conduct an economic analysis on the cost of conventional therapy as compared to biologic therapy and the direct/indirect costs of disease management in patients with refractory psoriatic arthritis (PsA). Primary outcomes are to qualify the economic burden of refractory PsA care. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Arthritis, Psoriatic, Psoriasis
- How many people
- 107 participants
- Where
- 9 sitesItaly
- Study dates
- Feb 2005to Jun 2011
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with PsA who are failure to the conventional treatments according to the local recommendations, will be enrolled in the study through tertiary referrals centers (HRCs i.e., Hospital Rheumatolgic Centers).
Who may be able to join
- Eighteen years of age or older
- Inflammatory arthropathy associated with psoriasis meet the ACR criteria for PsA
- Patients with diagnosis of active and progressive PsA who have failure with conventional treatments
Who cannot join
- Significant concurrent medical diseases including cancer or a history of cancer, uncontrolled congestive heart failure, myocardial infarctions within 12 months or other clinically significant cardiovascular diseases, immunodeficiency syndromes or concomitant infectious diseases.
Trial locations and contacts
9 sites in 1 country.
9 sites in 1 country
Italy9 sites
Pfizer Investigational Site
Benevento
Pfizer Investigational Site
Cagliari, Cagliari, 09100
Pfizer Investigational Site
Florence, Italy, 50139
Pfizer Investigational Site
Naples, Campania, 80131
Pfizer Investigational Site
Padova, Padova, 35128
Pfizer Investigational Site
Potenza, Potenza, 85100
Pfizer Investigational Site
Prato, FI - Italy, 50047
Pfizer Investigational Site
Reggio Emilia, Reggio Emilia, 42100
Pfizer Investigational Site
Roma, Roma, 00161
About this study
Official title: An Observational Study to Evaluate the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy
The purpose of this study is to conduct an economic analysis on the cost of conventional therapy as compared to biologic therapy and the direct/indirect costs of disease management in patients with refractory psoriatic arthritis (PsA). Primary outcomes are to qualify the economic burden of refractory PsA care. The secondary outcomes are to assess efficacy, safety, and cost effectiveness of different therapies.
- Conditions
- Arthritis, Psoriatic, Psoriasis
- Keywords
- Rheumatoid Arthritis
- Medical subject headings
- Arthritis, Psoriasis, Arthritis, Rheumatoid
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Cost Per Participant Per Month at Month 12
Overall cost per participant per month was evaluated as part of health economics evaluation to quantify burden of Refractory PsA and its treatment, resources absorbed by the disease and its care into monetary terms. Overall cost was defined as sum of direct and indirect costs (productivity losses). Direct costs included cost of following cost variables: pharmacological treatment; hospitalizations; diagnostic examinations, laboratory analysis and specialist visits; transports.
Measured: Month 12
Mean Cost Per Participant Per Month at Month 60
Overall cost per participant per month was evaluated as part of health economics evaluation to quantify burden of Refractory PsA and its treatment, resources absorbed by the disease and its care into monetary terms. Overall cost was defined as sum of direct and indirect costs (productivity losses). Direct costs included cost of following cost variables: pharmacological treatment; hospitalizations; diagnostic examinations, laboratory analysis and specialist visits; transports.
Measured: Month 60
Incremental Cost-effectiveness Ratio (ICER)
ICER: ratio of the incremental cost of treatment over the incremental effectiveness. Incremental cost = difference in cost between baseline and month 60. Effectiveness was defined as quality adjusted life year (QALY) gained, i.e. difference in Euro Quality of Life 5 Dimension (EQ-5D)- health state profile utility score between baseline and month 60. (EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Total score range -0.594 to 1.000; higher score indicates a better health state.)
Measured: Baseline up to Month 60
Secondary outcomes (25)
Number of Participants With Assessment in Ankylosing Spondylitis (ASAS) 20 Response
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) participants. ASAS = 4 domains: participant global assessment of disease activity, pain, function, inflammation. ASAS 20 = 20% improvement from baseline and an absolute change >= 10 units on a 0-100 scale (0=no disease activity; 100=high disease activity) for >= 3 domains, and no worsening in remaining domain.
Measured: Month 6, Month 12, Month 18, Month 24, Month 60
Number of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)
PsARC is comprised of 4 clinical improvement criteria: 1 unit (0-5 Likert scale) improvement on the Physician Global Assessment (PGA); 20% (0-100 scale) improvement on the participant assessments; and 30% reduction in the number of tender joints; and 30% reduction in the number of swollen joints. To achieve a clinical response, the participant must improve in 2 of the 4 PsARC criteria, 1 of which has to be the number of tender or swollen joints and none of the 4 scores could worsen.
Measured: Month 6, Month 12, Month 18, Month 24, Month 60
Psoriasis Area and Severity Index (PASI)
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0= 0% to 6= 90-100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section*area score*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0= no disease to 72= maximal disease.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Bath Ankylosing Spondylitis Functional Index (BASFI)
BASFI is a validated self assessment tool that determines the degree of functional limitation in AS. Utilizing a Visual Analog Scale (VAS) of 0-10 (0 = easy, 10 = impossible), participants answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a sum of the scores of the 10 questions. Total possible score range: 0-100, where higher score referred to higher impairment in the functional ability.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
BASDAI is a validated self assessment tool used to determine disease activity in participant with Ankylosing Spondylitis (AS). Utilizing a VAS of 0-10 (0=none and 10=very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The final BASDAI score averages the individual assessments for a final score range of 0-10.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Bath Ankylosing Spondylitis Radiology Index (BASRI)
BASRI- Radiographs of participants with AS were scored using the New York criteria for the sacroiliac joints on a scale of 2 to 4, the lumbar and cervical spine on a scale of 0 to 4 (0 = normal, 1 = suspicious, 2 = mild, 3 = moderate, 4 = severe). These 3 scores were added together to produce the BASRI-spine (BASRI-s) score (range 2 to 12). Similarly, hip joints were scored on a scale of 0 to 4 to give BASRI-hip (BASRI-h). Sum of BASRI-s and BASRI-h produced BASRI-total (BASRI-t) score; total range 2 to 16, higher score represented worse health state.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Modified Schober's Test
Measurement in centimeters (cm) of the distance between marks originally placed while the participant was standing erect 10 cm above and 5 cm below the midpoint of a line that joints the posterior superior iliac spines. Distance between marks was re-measured with participant maximally bend forward, knees fully extended, with spine in full flexion.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Chest Expansion Measurement
Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line).
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Occiput-to-wall Distance
Occiput-to-wall distance: distance between the occiput (posterior or back portion of the head) and the wall when the participant stood with heels and shoulder against the wall and the back straight.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Maastricht Ankylosing Spondylitis Enthesis Score (MASES)
Assessment of enthesitis was performed in the following 7 domains: 1) 1st costochondral joint left and right, 2) 7th costochondral joint left and right, 3) posterior superior iliac spine left and right, 4) anterior superior iliac spine left and right, 5) iliac crest left and right, 6) 5th lumbar spinous process and 7) proximal insertion of Achilles tendon left and right. Each domain was graded for the presence (1) and absence (0) of tenderness yielding total MASES ranging from 0 (no tenderness) to 13 (worst possible score; severe tenderness).
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Number of Swollen and Tender Joints
Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
ACR20 response: greater than or equal to (>=) 20 percent (%) improvement in tender joint count; >= 20% improvement in swollen joint count; and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
Measured: Month 6, Month 12, Month 18, Month 24, Month 60
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
ACR50 response: >= 50% improvement in tender joint count; >= 50% improvement in swollen joint count; and >= 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Measured: Month 6, Month 12, Month 18, Month 24, Month 60
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
ACR70 response: >= 70% improvement in tender joint count; >= 70% improvement in swollen joint count; and >= 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Measured: Month 6, Month 12, Month 18, Month 24, Month 60
Radiographic Score Based on Wassenberg
Radiographic score based on wassenberg consisted of 2 sub-scores, proliferation score (PS) assessing bone proliferation and destruction score (DS) assessing joint surface destruction. Score range for PS and DS was 0 to 160 (where higher score represented higher bone proliferation) and 0 to 200 (where higher score represented higher destruction), respectively. Total score = sum of PS and DS (range 0 to 360); higher score represented worse state.
Measured: Baseline, Month 12, Month 24, Month 60
Patient Global Assessment (PtGA) of Disease Activity Score
Measured using a 100 millimeter (mm) VAS ranging from 0 mm = very good to 100 mm = very bad.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Physician Global Assessment (PGA) of Disease Activity
Physician Global Assessment of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no disease activity.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Visual Analogue Scale for Pain (VAS-pain)
100 mm line (VAS) marked by participant. Intensity of pain range (over past week): 0 = no pain to 100 = worst possible pain.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Erythrocyte Sedimentation Rate (ESR)
ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 millimeter/hour (mm/hr). A higher rate is consistent with inflammation.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
C-reactive Protein (CRP)
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Duration of Morning Stiffness
Duration of morning stiffness is defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in minutes (if none was present = 0; if morning stiffness was continuing, average of duration of stiffness over the past 3 days was reported; if stiffness persisted the entire day, 1440 minutes [24 hours*60 minutes] was recorded).
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Health Assessment Questionnaire (HAQ)
HAQ: participant-reported assessment of ability to perform tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) hygiene; and 8) common activities over past week. Each item scored on 4-point Likert scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Euro Quality of Life (EQ-5D)- Health State Profile Utility Score
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. It assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
36-Item Short-Form Health Survey (SF-36)
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and was reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0-100 where higher scores represented higher level of functioning.
Measured: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Mar 2006 (estimated)
- Study startFeb 2005
- Primary completionJun 2011
- Study completionJun 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Arthritis, Psoriatic, PsoriasisStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 107 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00303186
- Sponsor's protocol ID
- 0881A-101750
- Other IDs
- B1801109
- Status last verified
- Jun 2012
- First submitted
- 14 Mar 2006
- Last updated
- 30 Jul 2012
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Olivieri I, Cortesi PA, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Ciampichini R, Cutro MS, Mathieu A, Matucci-Cerinic M, Punzi L, Scarpa R, Mantovani LG; PACE Working Group. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. Clin Exp Rheumatol. 2016 Jan-Feb;34(1):68-75. Epub 2015 Dec 3.
PubMed 26633622
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Observational Study to Evaluate the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy
- ClinicalTrials.gov ID
- NCT00303186
- Acronym / sponsor ID
- 0881A-101750
- Conditions
- Arthritis, Psoriatic, Psoriasis
- Keywords
- Rheumatoid Arthritis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 107 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Feb 2005
- Primary completion
- Jun 2011 (actual)
- Study completion
- Jun 2011 (actual)
- First posted
- 15 Mar 2006 (estimated)
- Results
- Posted 30 Jul 2012
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to conduct an economic analysis on the cost of conventional therapy as compared to biologic therapy and the direct/indirect costs of disease management in patients with refractory psoriatic arthritis (PsA). Primary outcomes are to qualify the economic burden of refractory PsA care. The secondary outcomes are to assess efficacy, safety, and cost effectiveness of different therapies.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with PsA who are failure to the conventional treatments according to the local recommendations, will be enrolled in the study through tertiary referrals centers (HRCs i.e., Hospital Rheumatolgic Centers).
Key inclusion criteria (3 listed)
- Eighteen years of age or older
- Inflammatory arthropathy associated with psoriasis meet the ACR criteria for PsA
- Patients with diagnosis of active and progressive PsA who have failure with conventional treatments
Key exclusion criteria (1 listed)
- Significant concurrent medical diseases including cancer or a history of cancer, uncontrolled congestive heart failure, myocardial infarctions within 12 months or other clinically significant cardiovascular diseases, immunodeficiency syndromes or concomitant infectious diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mean Cost Per Participant Per Month at Month 12
Time frame: Month 12
Overall cost per participant per month was evaluated as part of health economics evaluation to quantify burden of Refractory PsA and its treatment, resources absorbed by the disease and its care into monetary terms. Overall cost was defined as sum of direct and indirect costs (productivity losses). Direct costs included cost of following cost variables: pharmacological treatment; hospitalizations; diagnostic examinations, laboratory analysis and specialist visits; transports.
Mean Cost Per Participant Per Month at Month 60
Time frame: Month 60
Overall cost per participant per month was evaluated as part of health economics evaluation to quantify burden of Refractory PsA and its treatment, resources absorbed by the disease and its care into monetary terms. Overall cost was defined as sum of direct and indirect costs (productivity losses). Direct costs included cost of following cost variables: pharmacological treatment; hospitalizations; diagnostic examinations, laboratory analysis and specialist visits; transports.
Incremental Cost-effectiveness Ratio (ICER)
Time frame: Baseline up to Month 60
ICER: ratio of the incremental cost of treatment over the incremental effectiveness. Incremental cost = difference in cost between baseline and month 60. Effectiveness was defined as quality adjusted life year (QALY) gained, i.e. difference in Euro Quality of Life 5 Dimension (EQ-5D)- health state profile utility score between baseline and month 60. (EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Total score range -0.594 to 1.000; higher score indicates a better health state.)
25 secondary outcomes
Number of Participants With Assessment in Ankylosing Spondylitis (ASAS) 20 Response
Time frame: Month 6, Month 12, Month 18, Month 24, Month 60
Number of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)
Time frame: Month 6, Month 12, Month 18, Month 24, Month 60
Psoriasis Area and Severity Index (PASI)
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Bath Ankylosing Spondylitis Functional Index (BASFI)
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Bath Ankylosing Spondylitis Radiology Index (BASRI)
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Modified Schober's Test
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Chest Expansion Measurement
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Occiput-to-wall Distance
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Maastricht Ankylosing Spondylitis Enthesis Score (MASES)
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Number of Swollen and Tender Joints
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
Time frame: Month 6, Month 12, Month 18, Month 24, Month 60
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
Time frame: Month 6, Month 12, Month 18, Month 24, Month 60
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
Time frame: Month 6, Month 12, Month 18, Month 24, Month 60
Radiographic Score Based on Wassenberg
Time frame: Baseline, Month 12, Month 24, Month 60
Patient Global Assessment (PtGA) of Disease Activity Score
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Physician Global Assessment (PGA) of Disease Activity
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Visual Analogue Scale for Pain (VAS-pain)
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Erythrocyte Sedimentation Rate (ESR)
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
C-reactive Protein (CRP)
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Duration of Morning Stiffness
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Health Assessment Questionnaire (HAQ)
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Euro Quality of Life (EQ-5D)- Health State Profile Utility Score
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS)
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
36-Item Short-Form Health Survey (SF-36)
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 60
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2012.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 26633622Olivieri I, Cortesi PA, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Ciampichini R, Cutro MS, Mathieu A, Matucci-Cerinic M, Punzi L, Scarpa R, Mantovani LG; PACE Working Group. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. Clin Exp Rheumatol. 2016 Jan-Feb;34(1):68-75. Epub 2015 Dec 3.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Arthritis, Psoriatic, Psoriasis
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
Recruiting
Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis
Rhumatoid Arthisis, Spondyloarthritis (SA)
RecruitingPhase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Psoriatic Arthritis, Axial Spondyloarthritis
RecruitingPhase 4
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
Psoriatic Arthritis (PsA)
Active, not recruitingPhase 3
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Psoriatic Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Arthritis, Psoriatic, Psoriasis, run by Pfizer at 9 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jul 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 30 Jul 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Cost Per Participant Per Month at Month 12 (time frame: Month 12). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00303186, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2012.